Physician profile
Shutish C Patel
NPI 1447273511
$73,319.90
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $9,251 · 2021: $23K · 2022: $19K · 2023: $12K · 2024: $9,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $2,512 · Travel and Lodging: $294 · Education: $10.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,525.00 |
| Food and Beverage | $2,511.58 |
| Travel and Lodging | $293.62 |
| Education | $10.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $60,365.24 | 2021-2024 | |
| Allergan, INC. | $11,128.75 | 2019-2021 | |
| Amgen INC. | $322.91 | 2019-2024 | Uplizna |
| Csl Behring | $219.50 | 2020-2022 | |
| Sk Life Science, INC. | $197.74 | 2024 | Xcopri |
| Mdd US Operations, LLC | $193.11 | 2024 | Gocovri, Apokyn |
| Alexion Pharmaceuticals, INC. | $126.00 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $122.07 | 2022 | |
| Akcea Therapeutics, INC. | $122.02 | 2019 | |
| Biogen, INC. | $116.67 | 2022-2023 | Vumerity |
| Emd Serono, INC. | $100.00 | 2024 | Mavenclad |
| E.R. Squibb & Sons, L.L.C. | $98.19 | 2024 | Zeposia |
| Pfizer INC. | $60.20 | 2023-2024 | |
| Horizon Therapeutics Plc | $37.13 | 2023 | Uplizna |
| Upsher-Smith Laboratories LLC | $36.10 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $22.56 | 2024 | |
| Ucb, INC. | $22.10 | 2024 | Briviact |
| Neurocrine Biosciences, INC. | $14.97 | 2024 | Ingrezza |
| Adamas Pharmaceuticals, INC. | $14.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shutish Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.